OrbiMed’s Vera Therapeutics VERA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-369,596
Closed -$15.9M – 153
2026
Q2
$15.9M Hold
369,596
– – 0.29% 73
2026
Q1
$14.9M Buy
369,596
+16,096
+5% +$693K 0.29% 65
2025
Q4
$17.9M Buy
+353,500
New +$12.6M 0.37% 64
2025
Q2
– Sell
-481,065
Closed -$11.6M – 121
2025
Q1
$11.6M Sell
481,065
-261,507
-35% -$8.4M 0.28% 57
2024
Q4
$31.4M Buy
742,572
+66,700
+10% +$2.95M 0.65% 44
2024
Q3
$29.9M Hold
675,872
– – 0.54% 49
2024
Q2
$24.5M Hold
675,872
– – 0.48% 52
2024
Q1
$29.1M Sell
675,872
-842,243
-55% -$30M 0.53% 51
2023
Q4
$23.3M Hold
1,518,115
– – 0.47% 61
2023
Q3
$20.8M Sell
1,518,115
-238,685
-14% -$4.1M 0.44% 62
2023
Q2
$28.2M Buy
1,756,800
+394,400
+29% +$3.56M 0.51% 59
2023
Q1
$10.6M Buy
+1,362,400
New +$10.5M 0.21% 85

Other funds holding VERA

OrbiMed's VERA Position: Q3 2026 in Review

OrbiMed sold out of Vera Therapeutics (VERA) in Q3 2026, closing a stake of 369,596 shares — an estimated $15.9M sold.

OrbiMed first reported a position in VERA in Q1 2023 and held it in 12 quarters. The position peaked at $31.4M in Q4 2024. 224 funds tracked by Wall St. Rank hold VERA as of Q3 2026.

  • OrbiMed reported no remaining Vera Therapeutics position as of Q3 2026 after selling out during the quarter.
  • OrbiMed sold 369,596 Vera Therapeutics shares in Q3 2026, an estimated $15.9M.
  • OrbiMed first reported a position in Vera Therapeutics in Q1 2023 and held it in 12 quarters.
  • OrbiMed's Vera Therapeutics position peaked at $31.4M in Q4 2024.
  • 224 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2026.

Based on OrbiMed's 13F filing for Q3 2026, filed 16 Nov 2026.